Sign in

    Charles Moore

    Research Analyst at Robert W. Baird & Co.

    Charles Moore is an equity research analyst at Robert W. Baird & Co., specializing in covering select companies within his designated sector. He delivers in-depth analysis and recommendations on firms such as those in his coverage universe while leveraging a research-driven approach to generate actionable investment insights and achieve robust performance metrics. Moore began his finance career after rigorous academic training, bringing experience from both foundational analyst roles and his tenure at Baird, where he has earned a reputation for thorough financial modeling and timely market commentary. He maintains active securities industry credentials, reflecting compliance with key FINRA requirements and industry best practices.

    Charles Moore's questions to MiNK Therapeutics (INKT) leadership

    Charles Moore's questions to MiNK Therapeutics (INKT) leadership • Q3 2024

    Question

    Charles Moore from Robert W. Baird & Co., on behalf of Jack Allen, asked for additional details on the trial design, endpoints, and desired outcomes for the upcoming graft-versus-host disease (GVHD) program.

    Answer

    President and CEO Dr. Jennifer Buell explained that the GVHD trial is advancing towards a first-in-human study planned for next year, targeting high-risk patients undergoing hematopoietic stem cell transplantation. The primary goals are to improve engraftment success and mitigate the risk of GvHD. She mentioned the control arm would likely be physician's choice, primarily corticosteroids, and promised that more formal details on the trial design and leadership would be shared on the next earnings call.

    Ask Fintool Equity Research AI

    Charles Moore's questions to Crinetics Pharmaceuticals (CRNX) leadership

    Charles Moore's questions to Crinetics Pharmaceuticals (CRNX) leadership • Q3 2024

    Question

    Charles Moore, on for Brian Skorney, asked about the potential advantages of Crinetics' nonpeptide approach for its GLP-1 and GIP assets relative to other peptide-based therapies in the obesity space.

    Answer

    CEO R. Struthers highlighted that small molecules overcome the manufacturing and delivery limitations inherent to peptides. He explained that this allows for greater flexibility in tuning physicochemical properties to optimize pharmacologic activity and pharmacokinetics, ultimately enabling the creation of a superior clinical profile that can be produced at scale.

    Ask Fintool Equity Research AI